HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
ADC
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
RemeGenChina - Yantai
1 program1
Disitamab Vedotin combined with RadiotherapyPhase 2ADC1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
RemeGenDisitamab Vedotin combined with Radiotherapy
Clinical Trials (1)
Total enrollment: 30 patients across 1 trials
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
Start: Sep 2025Est. completion: Dec 202830 patients
Phase 2Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.